Featured Research

from universities, journals, and other organizations

Promising stem cell therapy for leukemia patients

Date:
April 2, 2013
Source:
Fraunhofer-Gesellschaft
Summary:
Leukemia patients receive a bone marrow transplant, which allows them to build a "new" immune system. However, this immune system not only attacks cancer cells but healthy tissue too. Special antibodies will be used to protect healthy tissue in future.

Leukemia patients receive a bone marrow transplant, which allows them to build a "new" immune system. However, this immune system not only attacks cancer cells but healthy tissue too. Special antibodies will be used to protect healthy tissue in future.

Related Articles


Not too long ago, leukemia left us with no chance. Today doctors can give patients hope by transplanting bone marrow, the starting point of a "new" immune system. These transplanted cells replace the diseased, blood-building stem cells in the bone marrow and take over their job of producing healthy blood cells, while also destroying leukemia cells. The problem is that this immune system originates from a foreign body and therefore can also attack healthy tissue in the patient. The skin, liver, and intestine are most affected by these attacks -- their cells can be destroyed and the organs damaged, sometimes so severely as to cause organ failure. The medical term for this phenomenon is graft-versus-host disease (GvHD), and the scale of the problem posed by this misdirected immune response is illustrated by statistics revealing that up to 50 percent of all patients ultimately suffer from GvHD-induced damage; in up to 20 percent of cases this damage is fatal. Not to ignore the further risk: that one in five leukemia patients suffer a relapse after the transplant.

In order to combat the cancer effectively, doctors give leukemia patients chemotherapy and radiation therapy before the transplant. These treatments destroy the patient's entire blood-building system, creating space for the donor's healthy cells. Any cancer cells that might survive this treatment are identified and destroyed by the new immune cells. So that the "foreign" immune system does not turn against healthy tissue, doctors additionally give patients immunosuppressants to artificially suppress the immune system. There is a fine balance to be struck here, as immunosuppressants not only inhibit GvHD but also the desired immune response, i.e. killing off the cancer cells.

Minimizing the risk of a misdirected immune reaction

Researchers at the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig are investigating how to improve the situation for leukemia sufferers. "Our goal is to avoid GvHD without changing how the new immune effect acts on the tumor," says Dr. Stephan Fricke, head of the Immune Tolerance unit at the IZI and doctor at the Department of Hematology and Oncology, University Hospital Leipzig. "Our hopes are pinned on monoclonal antibodies, which specifically bind to the surface of immune cells and prevent the immune cells reacting adversely with the patient's tissue." It's particularly important that the antibodies also act on the blood stem cells to be transplanted and on all immune cells that develop from them. This allows researchers to modulate the cells in advance of transplantation, causing them to "tolerate" the patient's healthy tissue instead of attacking it. "We're then able to effectively reduce the risk of a GvHD without any side effects," explains Fricke. The antibodies do not alter the immune response against remaining cancer cells -- they are still destroyed as before. This reduces the risk of leukemia coming back after the transplant.

IZI scientists are currently collaborating with their colleagues from the Translational Centre for Regenerative Medicine at the Universitδt Leipzig on research into the cellular foundations of these effects. What is the optimum point at which to add the antibodies to the donor bone marrow? How many antibodies should be used? Setting out to answer these questions, researchers first simulate both GvHD and the human immune system using a variety of established models. They can then determine all relevant parameters based on the simulations.

The researchers have already provided proof of principle, i.e. they were able to demonstrate that the therapy works. Now initial tests are underway on mice with a human immune system. The scientists hope that a clinical study can begin before the year is out.


Story Source:

The above story is based on materials provided by Fraunhofer-Gesellschaft. Note: Materials may be edited for content and length.


Cite This Page:

Fraunhofer-Gesellschaft. "Promising stem cell therapy for leukemia patients." ScienceDaily. ScienceDaily, 2 April 2013. <www.sciencedaily.com/releases/2013/04/130402091248.htm>.
Fraunhofer-Gesellschaft. (2013, April 2). Promising stem cell therapy for leukemia patients. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2013/04/130402091248.htm
Fraunhofer-Gesellschaft. "Promising stem cell therapy for leukemia patients." ScienceDaily. www.sciencedaily.com/releases/2013/04/130402091248.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) — The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) — Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) — Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) — Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins